Scarica l'app Stockscreener
0.298
0.17%
-0.0005
Precedente Chiudi:
$0.2985
Aprire:
$0.2974
Volume 24 ore:
368.91K
Relative Volume:
0.56
Capitalizzazione di mercato:
$30.81M
Reddito:
$1.27M
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-5.7088
EPS:
-0.0522
Flusso di cassa netto:
$-5.28M
1 W Prestazione:
-3.87%
1M Prestazione:
+20.16%
6M Prestazione:
+2.83%
1 anno Prestazione:
-31.96%
Intervallo 1D:
$0.2959
$0.30
Intervallo di 1 settimana:
$0.2941
$0.3191
Portata 52W:
$0.235
$0.4549
IGC Pharma Inc Stock (IGC) Company Profile
Nome
IGC Pharma Inc
Settore
Industria
Telefono
301-983-0998
Indirizzo
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.298 | 28.66M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Borsa (IGC) Ultime notizie
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn
IGC Pharma earnings matched, revenue fell short of estimates - Investing.com
IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade
IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz
IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com
IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView
IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com
IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s regulatory execution Update Reveal? - Kalkine Media
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s cannabinoid research progress Update Reveal? - Kalkine Media
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to WatchPlus More in Focus - openPR.com
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to Watch – Plus More in Focus - FinancialContent
IGC Looks 21.6% Overvalued on GF Value™ - GuruFocus
IGC Pharma Advances CALMA Toward Q4 Topline Readout - ACCESS Newswire
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - Corsicana Daily Sun
IGC Pharma (IGC) Climbs 5% to $0.28, Testing Key Resistance at $0.29Statistical Arbitrage - vinanet.vn
IGC Pharma Inc (IGS1.DU) balance sheet - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma Inc (IGC) Stock News Today - TradingKey
Price to sales forward of IGC Pharma, Inc. – MUN:IGS1 - TradingView
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - openpr.com
IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss Marks 14.16% EPS BeatQuarterly Earnings Report - vinanet.vn
Microcaps MGRX, PRSO, IGC, KUST In the News to Watch - openPR.com
IGC Pharma, Inc. Revenue Breakdown – AMEX:IGC - TradingView
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign - The Batesville Daily Guard
IGC|IGC Pharma Inc|Price:0.266|Chg%:+0.002 - TradingKey
IGC Pharma Hovers Near Support as Slight Decline Tests $0.26 LevelRetail Volume - vinanet.vn
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 - TradingKey
IGC Pharma Inc (IGC) Cash Flow - TradingKey
IGC Pharma Inc (IGC) Balance Sheet - TradingKey
IGC Pharma Inc (IGC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IGC Pharma Inc (IGC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IGC Pharma Inc (IGC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IGC Pharma, Inc. Revenue Breakdown – SWB:IGS1 - TradingView
IGC Pharma, Inc. Revenue Breakdown – LS:A1T87A - TradingView
IGC Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Lack of Revenue DisclosureEPS Estimate Trend - Vinanet
IGC Pharma Inc (IGC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IGC Pharma Inc (IGS1.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
Price to earnings forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseCFO Commentary Report - vinanet.vn
IGC Q1 2026 Earnings: Loss Narrows on Lower Expenses; Stock Gains 1.44%High Estimate Range - vinanet.vn
IGC Pharma Inc Azioni (IGC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
IGC Pharma Inc Azioni (IGC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.13 |
656,410 |
84,000 |
4,649,088 |
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.00 |
49,999 |
0 |
910,751 |
| Moran James P | Director |
Apr 01 '26 |
Option Exercise |
0.00 |
130,000 |
0 |
1,235,735 |
| GRIMALDI CLAUDIA | PFO |
Apr 01 '26 |
Option Exercise |
0.15 |
238,462 |
36,000 |
1,372,714 |
| Mukunda Ram | CEO |
Feb 03 '26 |
Option Exercise |
0.00 |
50,000 |
0 |
860,752 |
| PRINS RICHARD K | Director |
Jan 19 '26 |
Option Exercise |
0.00 |
100,000 |
0 |
1,371,251 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):